Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Data Center ESS · Potential SDC Monetization · Operating Profit Turnaround / 2026-06-26 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | LTA · HBM Demand · Valuation Re-rating / 2026-05-27 Research
  • [Research] SK hynix (000660 / SKHY) – iM Securities | DRAM Pricing · ADR Listing · Multiple Recovery / 2026-04-24 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Capex Discipline · Cycle Stability / 2026-01-28 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2024 Earnings Presentation / 2025-01-24 IR Room
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28 Research

[Research] SK hynix (000660 / SKHY) – Kiwoom | Legacy Memory Pricing · Earnings Upgrades · Volume Growth / 2026-03-03

Posted on March 3, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Kiwoom Securities

Analyst : Yuak Pak

Investment Rating : BUY (Maintain)

Target Price : 1,300,000 KRW (Upgraded)

Core Momentum : Sharp legacy DRAM and NAND price increases are driving substantial earnings upgrades, while the memory cycle is expected to transition from price-led gains toward CapEx-supported volume growth as profitability strengthens.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price / Investment Rating: 1,300,000 KRW / BUY (Maintain)
  • Current Price (as of 2/27): 1,061,000 KRW
  • Market Capitalization: 75,617.7 billion KRW (7,561,772 million KRW / KOSPI 6,244.13pt)
  • Key Financial Metrics (2023 / 2024 / 2025F / 2026F):
    • Revenue: 32,766 billion KRW / 66,193 billion KRW / 97,147 billion KRW / 230,200 billion KRW
    • Operating Profit: -7,730 billion KRW / 23,467 billion KRW / 47,206 billion KRW / 170,077 billion KRW
    • Pre-tax Income: -11,658 billion KRW / 23,885 billion KRW / 50,465 billion KRW / 172,796 billion KRW
    • Net Income: -9,138 billion KRW / 19,797 billion KRW / 42,948 billion KRW / 134,350 billion KRW
    • EPS: -12,517 KRW / 27,182 KRW / 58,970 KRW / 184,469 KRW
    • PER: -11.3x / 6.4x / 11.0x / 5.8x
    • PBR: 1.9x / 1.7x / 4.1x / 3.1x
    • ROE: -15.6% / 31.1% / 45.1% / 73.5%

🚀 2. [Market Opportunities & Business Outlook]

  • Robust 1Q26 Earnings Expectations: First-quarter revenue is estimated at 45.9 trillion KRW (+40% QoQ) and operating profit at 32.3 trillion KRW (+69% QoQ), beating market consensus. Price forecasts for legacy DRAM and NAND have been revised upward by roughly +65% QoQ, driving substantial profit expansion.
  • Upward Revision of FY2026 Operating Profit to 170 Trillion KRW: Full-year earnings have been raised to 230 trillion KRW in revenue and 170 trillion KRW in operating profit (+260% YoY). The blended DRAM ASP growth forecast was lifted to +86% YoY (legacy DRAM up +145% YoY), while NAND price projections were raised to +135% YoY.
  • Inflection Point in the Memory Cycle: The steep price rally in legacy memory is approaching its final phase, signaling a transition toward a cycle driven by CapEx expansion and volume growth backed by enhanced profitability.

📝 Editor’s Comment (Perspective)

The analyst evaluates that as AI momentum broadens into the NAND sector, surging prices across legacy memories are fueling massive earnings upgrades, pushing the 2026 operating profit target to 170 trillion KRW. This perspective highlights the importance of anticipating a structural shift in the memory cycle from price-led gains to volume-driven expansion.

To determine whether this investment thesis is unfolding as projected, key items to monitor include the delivery of 32.3 trillion KRW in Q1 operating profit, the sustainability of price hikes across mobile and server memory, and shipment growth backed by increased CapEx. These developments can be tracked through upcoming quarterly and annual earnings releases, official corporate IR materials, and regulatory disclosures via DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – SK Securities | AI Memory · NAND Tiering · Earnings Re-rating / 2026-02-24
Next Post: [Research] LIG D&A (079550) – Hana Securities | Complementing Patriot · Cheongung-II Cost Competitiveness · KRW 26.2T Backlog / 2026-03-03

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Kiwoom | NAND Pricing · Fab Utilization · Earnings Upgrades / 2026-01-07 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Revenue Recognition · Guidance Revision Potential · Plant 5 Commercialization / 2026-04-23 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21 Research
  • [Research] Samsung Electro-Mechanics (009150) – DS Investment & Securities | MLCC Price Leverage · Capacity Cannibalization · Earnings Upward Revisions / 2026-07-31 Research
  • [Research] Samsung SDI (006400) – iM Securities | Surging AIDC ESS Demand · US Regulatory Tailwinds · Valuation Assessment / 2026-04-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | Broad Price Hikes · Si-Cap & Advanced Packaging · Full FC-BGA Utilization / 2026-06-09 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q2 2025 Earnings Presentation / 2025-07-31 IR Room

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme